卡瑞利珠单抗联合安罗替尼三线治疗晚期非小细胞肺癌的疗效观察  

Efficacy of Combination of Camrelizumab with Anlotinib as Third-line Therapy for Patients with Advanced Non-small Cell Lung Cancer

作　　者：张晓娟[1] 岳冬丽[1] 杨双宁[1] 郝娜 王丽萍[1] 董文杰[1] ZHANG Xiaojuan;YUE Dongli;YANG Shuangning;HAO Na;WANG Liping;DONG Wenjie(Department of Oncology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州450052

出　　处：《肿瘤防治研究》2023年第6期593-597,共5页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金面上项目(81872410)。

摘　　要：目的探讨卡瑞利珠单抗联合安罗替尼三线治疗晚期非小细胞肺癌的临床疗效及安全性。方法回顾性分析84例二线治疗进展后的晚期非小细胞肺癌患者的临床资料。其中44例接受卡瑞利珠单抗联合安罗替尼治疗的患者为观察组,40例接受单药安罗替尼治疗的患者为对照组。比较两组无进展生存期(PFS)、客观缓解率(ORR)、疾病控制率(DCR)和不良事件(AE)发生率。结果观察组的中位PFS长于对照组(7.0月vs.5.6月,P=0.001)。两组ORR及DCR差异无统计学意义(P=0.112,P=0.508)。两组AE及≥3级AE发生率差异均无统计学意义(P=0.222,P=0.112)。结论卡瑞利珠单抗联合安罗替尼三线治疗晚期非小细胞肺癌的临床疗效优于单用安罗替尼,且安全性良好。Objective To investigate the clinical efficacy and related adverse reactions of the combination of camrelizumab with anlotinib as the third-line therapy on advanced non-small cell lung cancer.Methods We retrospectively analyzed the clinical data of 84 patients with advanced non-small cell lung cancer after second-line treatment.According to different treatment methods,44 patients who received camrelizumab combined with anlotinib were included in the observation group,and 40 patients who received anlotinib alone were included in the control group.The PFS,ORR,DCR and incidence of adverse reactions were analyzed and compared between the two groups.Results The median PFS of the observation group was longer than that of the control group(7.0 vs.5.6 months,P=0.001).No statistically significant difference was observed in ORR,DCR,the incidence of adverse reactions or the incidence of adverse reactions above grade 3 between two groups(all P>0.05).Conclusion The clinical efficacy of camrelizumab combined with anlotinib as third-line therapy on advanced non-small cell lung cancer is better than anlotinib alone,and the safety is good.

关 键 词：卡瑞利珠单抗 安罗替尼 非小细胞肺癌 三线治疗 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]